Department of Radiology (B.H.B., W.Y., Y.Y.L., S.K.K.), Chonnam National University Medical School, Gwangju, Republic of Korea.
Department of Neurology (J.-T.K., M.S.P.), Chonnam National University Medical School, Gwangju, Republic of Korea.
Stroke. 2021 May;52(5):1601-1608. doi: 10.1161/STROKEAHA.120.033551. Epub 2021 Apr 1.
This study aimed to investigate the effectiveness and safety of intravenous infusion of tirofiban after emergent angioplasty with or without stenting in patients with intracranial atherosclerotic stenosis-related large-vessel occlusion stroke.
We performed a retrospective case series study of 98 patients who underwent thrombectomy followed by angioplasty with or without stenting to treat intracranial atherosclerotic stenosis-related large-vessel occlusion. Patients were divided into 2 groups: those who received continuous intravenous infusion of tirofiban for 12 hours after procedure (intravenous tirofiban group, n=30) and those who did not receive postprocedural intravenous tirofiban (control group, n=68). The following treatment outcomes in the 2 groups were compared: early reocclusion of treated arteries on computed tomography angiography, parenchymal hematoma, symptomatic hemorrhage, and 90-day functional outcome.
Early reocclusion occurred in 18 patients (18.4%). The rate of early reocclusion was significantly lower in the intravenous tirofiban group than in the control group (3.3% versus 25%, P<0.001). The rates of parenchymal hematoma, symptomatic hemorrhage, 90-day good outcome, and mortality were not significantly different between the 2 groups. In multivariate logistic analysis, the only independent predictor of early reocclusion was no use of intravenous tirofiban (odds ratio, 9.212 [95% CI, 1.155-73.495], P=0.036). A good outcome (90-day modified Rankin Scale score of 0-2) was significantly less frequent in patients with early reocclusion than in those without it (16.7% versus 72.5%, P<0.001).
The use of intravenous tirofiban for 12 hours was associated with decreased risk of early reocclusion of treated arteries, with no increased risk of hemorrhage after emergent angioplasty, with or without stenting, in patients with intracranial atherosclerotic stenosis-related large-vessel occlusion stroke. Early reocclusion was associated with a poor outcome in such cases.
本研究旨在探讨血管成形术联合或不联合支架置入治疗颅内动脉粥样硬化性狭窄相关大血管闭塞性卒患者中,血管内输注替罗非班的有效性和安全性。
我们对 98 例行血栓切除术联合血管成形术联合或不联合支架置入治疗颅内动脉粥样硬化性狭窄相关大血管闭塞的患者进行了回顾性病例系列研究。患者分为两组:术后 12 小时内持续静脉输注替罗非班组(n=30)和未接受术后静脉输注替罗非班组(n=68)。比较两组以下治疗结局:CT 血管造影显示治疗动脉早期再闭塞、实质血肿、症状性出血和 90 天功能结局。
18 例(18.4%)患者发生早期再闭塞。静脉输注替罗非班组早期再闭塞发生率明显低于对照组(3.3%比 25%,P<0.001)。两组实质血肿、症状性出血、90 天良好结局和死亡率无显著差异。多变量逻辑回归分析显示,早期再闭塞的唯一独立预测因素是未使用静脉替罗非班(比值比,9.212[95%CI,1.155-73.495],P=0.036)。与无早期再闭塞者相比,早期再闭塞患者 90 天改良Rankin 量表评分 0-2 分的良好结局明显较少(16.7%比 72.5%,P<0.001)。
在颅内动脉粥样硬化性狭窄相关大血管闭塞性卒患者中,血管成形术联合或不联合支架置入术后 12 小时内使用替罗非班可降低治疗动脉早期再闭塞的风险,不增加出血风险,且不增加症状性出血风险。此类患者的早期再闭塞与不良结局相关。